Related Experiment Video
Updated: Aug 6, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers
Abhishek Chauhan1, Ankush Kumar1, Ankit Awasthi1
1Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
Nanocarriers offer a promising solution for epilepsy treatment by improving drug delivery to the brain. These advanced systems enhance antiepileptic drug efficacy and reduce side effects, paving the way for better seizure control.
Area of Science:
- Neurology
- Nanomedicine
- Pharmacology
Background:
- Epilepsy affects 50 million globally, characterized by recurrent seizures due to abnormal neuronal activity.
- Conventional epilepsy treatments face limitations like poor blood-brain barrier (BBB) penetration, drug resistance, and adverse effects.
- This review focuses on nanocarrier-based drug delivery systems to overcome these therapeutic challenges.
Purpose of the Study:
- To review recent advancements in nanocarrier-based drug delivery systems for epilepsy treatment.
- To evaluate the potential of various nanocarriers in enhancing antiepileptic drug efficacy.
- To summarize the progress and future prospects of nanomedicine in managing epilepsy.
Main Methods:
- A comprehensive review of peer-reviewed articles, patents, and clinical studies was performed.
- Evaluation of lipid-based, vesicular, polymeric, dendrimer, and inorganic nanocarriers.
- Analysis of formulation strategies, BBB transport mechanisms, and therapeutic applications.
Main Results:
- Nanocarriers improve solubility, stability, bioavailability, and targeted brain delivery of antiepileptic drugs.
- Various nanocarriers (liposomes, nanoparticles, dendrimers) show enhanced BBB penetration and seizure control in preclinical studies.
- Challenges include large-scale manufacturing, long-term safety, regulatory hurdles, and clinical translation.
Conclusions:
- Nanomedicine offers a promising strategy for targeted brain drug delivery in epilepsy.
- Nanocarriers can overcome limitations of conventional therapies, improving treatment outcomes.
- Further research, safety evaluations, and clinical validation are crucial for successful translation.
More Related Videos
14:14Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...